TrialNature communications2025

Anlotinib plus toripalimab as a first-line treatment in patients with advanced gastric cancer and performance status 2: the phase II APICAL-GC trial.

Ke Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.